

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES  
EXCHANGE ACT OF 1934**

**Date of Report: November 10, 2022**

**Commission File Number: 001-36891**

**Collectis S.A.  
(Exact Name of registrant as specified in its charter)**

**8, rue de la Croix Jarry  
75013 Paris, France  
+33 1 81 69 16 00  
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F [  ]    Form 40-F [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

**EXHIBIT INDEX**

**Exhibit**    **Title**

[99.1](#)        [Press release, dated November 10, 2022](#)

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Collectis S.A.  
(Registrant)

Date: November 10, 2022

/s/ André Choulika  
André Choulika  
Chief Executive Officer

## Collectis Publishes Manuscript in *Frontiers Bioengineering and Biotechnology* Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Collectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published a manuscript in *Frontiers Bioengineering and Biotechnology* demonstrating the feasibility of efficient multiplex gene engineering using a combination of two different molecular tools: Collectis’ TALEN® gene editing technology (TALE nuclease) and a TALE-BE (TALE Base editor).

TALE base editors are a recent and very important addition to the gene editing landscape. This approach does not create DNA double strand breaks as does CRISPR/Cas9, or other engineered nucleases, and is a promising therapeutic strategy for genetic diseases. A key aspect to broaden the scope of possible applications is our comprehension of design rules.

Collectis used a screening approach to gain in-depth insights into the editing rules driving TALE-BE activity and applied this knowledge to design highly efficient TALE-BE compatible with potential therapeutic application. Moreover, TALE-BE show insignificant levels of by-products such as indels.

Collectis scientists combined two molecular tools, a TALEN® and a TALE-BE, to perform a double gene Knock Out (KO) of *TRAC* and *CD52*, a combination of target genes used for allogeneic CAR T-cell adoptive therapies. This combination of molecular tools paves the way to simultaneous multiplex gene engineering with more controllable outcomes.

“A multiplex/multitool strategy presents several advantages: firstly, it prevents the creation of translocations often observed with the simultaneous use of several nucleases. Secondly, it allows for the possibility of going beyond multiple knock-outs while still allowing gene knock-in at the nuclease target site, altogether extending the scope of possible application,” said Alex Juillerat, Ph.D., Vice President Gene Editing & New York Lab Head at Collectis. “The precise positional rules we have determined for TALE-BE will allow Collectis to unleash the full potential of these technologies for future applications.”

### **Research data showed that:**

- Employing a medium/high throughput strategy, Collectis gained in-depth insight of the editing rules in cellulo, while excluding confounding factors.
- Designed TALE-BE targeting *CD52* achieved very high frequency of gene knock-out (up to 80% of phenotypic *CD52* knock out).
- When TALE-BE was combined with a TALEN® targeting the *TRAC* locus, very high frequency of double gene knock-out (up to 75% of phenotypic double gene knock-out) was achieved without the creation of translocations between the two targeted loci.

This article is available on *Frontiers in Bioengineering and Biotechnology* website by clicking on this link.

### **About Collectis**

Collectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Collectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of experience and expertise in gene editing, Collectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Collectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Collectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit [www.collectis.com](http://www.collectis.com). Follow Collectis on social media: @collectis, LinkedIn and YouTube.

### **For further information, please contact:**

#### **Media contacts:**

Pascalynne Wilson, Director, Communications, +33 (0)7 76 99 14 33, [media@collectis.com](mailto:media@collectis.com)  
Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300

#### **Investor Relation contact:**

Arthur Stril, Chief Business Officer, +1 (347) 809 5980, [investors@collectis.com](mailto:investors@collectis.com)  
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577

### **Forward-looking Statements**

This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “intend,” “expect,” “plan,” “scheduled,” “could,” “may” and “will,” or the negative of these and similar expressions.

These forward-looking statements, which are based on our management's current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the potential of our innovation programs. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2021 and subsequent filings Collectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

#### **Attachment**

- TALE\_Manuscript\_PR (<https://ml.globenewswire.com/Resource/Download/e0ccc9fc-b1da-46ea-a009-e6daf39857b8>)